Logo

Codex DNA SARS-CoV-2 Synthetic Genomes for UK and South Africa Variants

Mar 17, 2021

Codex DNA has released full-length synthetic genomes for the emerging SARS-CoV-2 variants B.1.1.7 and B.1.351, identified in the UK and South Africa, respectively.

The genomes are synthesized de novo on Codex DNA's BioXp 3250 system and can be used in developing vaccines, therapeutics, and diagnostics for COVID-19 research. They can be activated for use in monoclonal antibody therapy or vaccine development or serve as diagnostic controls.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.